Provigil (Modafinil) Medication Teaching and Dosing
The standard dose of Provigil is 200 mg taken once daily in the morning, which is strongly recommended as first-line treatment for narcolepsy and idiopathic hypersomnia, with doses up to 400 mg/day well-tolerated but offering no consistent additional benefit beyond 200 mg. 1, 2
Standard Dosing Recommendations
Primary Indications
- Narcolepsy: 200 mg once daily in the morning 2
- Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS): 200 mg once daily in the morning 2
- Shift Work Sleep Disorder (SWSD): 200 mg approximately 1 hour before work shift starts 2
Dose Adjustments
- Higher doses (400 mg/day) are well-tolerated but lack consistent evidence of additional benefit over 200 mg 2
- Split dosing: For patients experiencing late-afternoon/evening sleepiness despite good morning response, a 400 mg split-dose regimen (morning and midday) may be superior to once-daily dosing for sustaining wakefulness throughout the entire day 3
- Severe hepatic impairment: Reduce dose to one-half (100 mg daily) 2
- Elderly patients: Consider lower doses due to reduced elimination 2
- Severe renal impairment: Inadequate safety data; use caution 2
Critical Patient Teaching Points
FDA Black Box Warnings and Serious Risks
Modafinil is a Schedule IV controlled substance with potential for abuse or dependency 1. However, it has notably lower abuse potential compared to amphetamines or methylphenidate 4.
Pregnancy and Contraception (Critical)
- May cause fetal harm based on animal data 1
- A 2018 pregnancy registry showed higher rates of major congenital anomalies in children exposed in utero 1
- Reduces effectiveness of oral contraceptives through enzyme induction 1, 2
- Women of childbearing potential must use alternative or additional contraceptive methods
Allergic Reactions
Instruct patients to immediately stop modafinil and notify physician if they develop:
- Rash, hives, or mouth sores
- Blisters or peeling skin
- Trouble swallowing or breathing
- Any related allergic phenomenon 2
Common Adverse Effects
Most adverse events are mild to moderate 5:
- Headache (most common, ~13-52% depending on study) 4, 5
- Nausea (5%)
- Nervousness (8%)
- Insomnia
- Diarrhea
- Dry mouth 1
Alcohol Interaction
Advise patients to avoid alcohol while taking Provigil 2
Drug Interactions Requiring Dose Adjustments
Medications Requiring Monitoring or Dose Reduction
Modafinil induces CYP3A4 and inhibits CYP2C19, creating multiple interaction pathways 2:
- Cyclosporine: Blood levels may decrease by 50%; monitor levels closely 2
- Warfarin: Monitor prothrombin time/INR more frequently 2
- Drugs metabolized by CYP2C19 (diazepam, propranolol, phenytoin): May have prolonged elimination; require dose reduction and toxicity monitoring 2
- Triazolam: Cmax and AUC decreased by 42% and 59% respectively 2
- Tricyclic antidepressants (clomipramine): One case report of increased levels; monitor closely 2
Timing Considerations with Other Stimulants
- Methylphenidate or dextroamphetamine: Absorption of modafinil may be delayed by approximately 1 hour when coadministered 2
- No significant pharmacokinetic alterations occur, but timing should be considered
Clinical Efficacy and Long-Term Use
Modafinil demonstrates sustained efficacy without tolerance development:
- Disease severity rated as "much improved" or "very much improved" in 58-59% of patients at 40 weeks 5
- No withdrawal phenomena (fatigue, vivid dreams, insomnia, hypersomnia) after treatment cessation 4
- Quality of life significantly improved in 6 of 8 SF-36 domains through 40 weeks 5
- Does not suppress cataplexy—separate treatment needed for this symptom 4, 6
Pharmacokinetic Teaching Points
- Peak plasma levels: 2-4 hours after dosing 4
- Half-life: 9-15 hours 4, 7
- Steady state: Reached after 3 daily doses 7
- Food: Does not significantly affect absorption 4
- Metabolism: Primarily hepatic to inactive metabolites 4
Practical Clinical Pearls
Modafinil does not affect nocturnal sleep parameters or the ability to nap when necessary 4, which distinguishes it from traditional amphetamines. Patients can still sleep when needed despite taking the medication.
The medication's stereospecific pharmacokinetics mean the d-enantiomer is eliminated three times faster than l-enantiomer 7, contributing to its unique pharmacological profile and lower abuse potential compared to other stimulants.
For patients requiring all-day coverage, consider that split-dose regimens (200 mg morning + 200 mg midday) significantly improve evening wakefulness compared to single 400 mg morning doses 3.